PlumX Metrics
Embed PlumX Metrics

Synthesis and in–vitro anti–HIV–1 evaluation of novel pyrazolo[4,3–c]pyridin–4–one derivatives

European Journal of Medicinal Chemistry, ISSN: 0223-5234, Vol: 183, Page: 111714
2019
  • 23
    Citations
  • 0
    Usage
  • 13
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

In our continuing efforts to find novel anti–HIV compounds, we have synthesized sixteen novel pyrazolo[4,3–c]pyridin–4–one derivatives. All the synthesized compounds were screened for anti–HIV activity against HIV–1 VB59 (R5, subtype C). Compounds 12a–12c and 12e were also tested against HIV–1 UG070 (X4, subtype D) in TZM–bl cell line. Compound 12c was found to be the most active against HIV–1 VB59 and HIV–1 UG070 with IC 50 value 3.67 μM and 2.79 μM, and therapeutic indices 185 and 243, respectively. The lead compound 12c inhibited the HIV-192/BR/018 (R5, subtype B) and drug resistant isolates, NIH-119 (X4/R5, subtype B) and NARI-DR (R5, subtype C) effectively. The activity of the lead compound was further confirmed by PBMC assays. The molecular docking data showed that the most active compound 12c binds in the non-nucleoside binding pocket of HIV-1 reverse transcriptase, which was confirmed by the ToA assay. Thus the study indicated that 12c may be considered as a NNRTI and further explored as a lead for anti-HIV drug development.

Bibliographic Details

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know